EMPOWERING PATIENTS & CAREGIVERS:
2017 EDUCATION, SUPPORT, & ADVOCACY ACCOMPLISHMENTS

### Serving Constituents

<table>
<thead>
<tr>
<th>1,007,000 connections with constituents</th>
<th>907,315 connections through education programs, resources, and support groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>11,777 inquiries answered by the IBD Help Center</td>
</tr>
<tr>
<td></td>
<td>1,158 pediatric patients at Camp Oasis</td>
</tr>
<tr>
<td></td>
<td>34,700 interactions with medical professionals through education programs and resources</td>
</tr>
<tr>
<td></td>
<td>6,161 constituents engaged in action alerts related to access to care</td>
</tr>
<tr>
<td></td>
<td>71 members of Congress in the Crohn's &amp; Colitis Caucus</td>
</tr>
</tbody>
</table>

### Increasing Awareness

<table>
<thead>
<tr>
<th>63,314 individuals raised funds and awareness through Take Steps, spin4 crohn’s &amp; colitis cures, and Team Challenge</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.8 million impressions for Crohn’s &amp; Colitis Awareness Week</td>
</tr>
<tr>
<td>2.7 million visits to crohnscolitisfoundation.org</td>
</tr>
</tbody>
</table>

### Surgery Education

This initiative provides IBD patients with empowering resources. These new resources enable patients to discuss surgery options and treatment plans with their doctors and make informed treatment decisions. Materials detail why surgery may be necessary, common surgical procedures, dispel surgery-related myths, and prepare patients for what to expect.

### Clinical Trials Community

35,805 engagements with patients, caregivers, and providers in this new initiative, designed to:
- Increase awareness of clinical trials and their benefits
- Inform patients and providers about local clinical trial opportunities
- Provide patients with support resources to increase their comfort level with clinical trials

---

Our mission: To cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases.
888-694-8872 • info@crohnscolitisfoundation.org • www.crohnscolitisfoundation.org
A CATALYST FOR CURES:
2017 RESEARCH ACCOMPLISHMENTS

**LEADING IBD RESEARCH**

**ADVANCED SCIENCE DRIVING TOWARD NEW TREATMENTS AND ULTIMATELY CURES**

- $28.4 million invested in research in 2017
- $330 million invested since the Foundation’s inception
- Nearly 200 active research projects

**ACCELERATING PROGRESS**

**DROVE EFFORTS TO ACCELERATE SCIENCE FROM NEW DISCOVERY TO OPTIMAL CARE**

- Launched IBD Plexus®, a first-of-its-kind research information exchange platform designed to transform how IBD research will be conducted and lead us to better treatments and cures faster.
- Enrolled 600 participants in the Study of a Prospective Adult Research Cohort with IBD (SPARC IBD), which aims to identify predictors of response to IBD therapies and relapse, leading to precision medicine strategies and new therapeutic targets.
- Launched the Entrepreneurial Investing Initiative to support the discovery and development of research-based products that specifically address the unmet needs of IBD patients.
- The Pediatric RISK Stratification Study identified measurable predictors of disease complications in newly diagnosed pediatric Crohn’s disease patients. Upon validation of the findings, we will seek to partner with a diagnostics company to develop a tool for every physician to use, to help with therapeutic decisions.

**DISEASE FACTORS**

**INCREASED UNDERSTANDING OF THE INFLUENCES THAT IMPACT IBD IN ORDER TO LEAD TO INDIVIDUALIZED THERAPIES, PREVENTIONS, AND CURES**

- Identified diet, stress, and viruses as priority areas for study in the Environmental Triggers Initiative, which is investigating the effect of environmental exposures on the onset and progression of IBD.
- DINE-CD enrollment began, the first-ever national study of dietary interventions comparing the Specific Carbohydrate Diet™ and Mediterranean-style diet in adult patients with Crohn’s disease.
- The Microbiome Initiative identified several microbial byproducts that have either beneficial or deleterious effects on wound healing of the intestinal wall, opening new avenues toward the development of microbiome-based therapies.
- Within the Genetics Initiative, three studies have started testing pharmacological compounds to block pro-inflammatory pathways and improve mucosal healing.

Our mission: To cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases.

888-694-8872 • info@crohnscolitisfoundation.org • www.crohnscolitisfoundation.org